Topics
November/December 2012 | Treatment Of Retinoblastoma In The First 3 Months Of Life: Bridge Therapy
Treatment of Retinoblastoma in the First 3 Months of Life: Bridge Therapy
David H. Abramson, MD, FACS
June 24, 2026
Kalaris to Present Phase 1a Data on VEGF/HSPG Biologic at ASRS 2026
Ollin Biosciences Raises $330 Million to Advance Phase 3 Development of VEGF/Ang2 bispecific Antibody
June 23, 2026
Oculgen Announces First US Patient Enrolled in STAT Trial of OCUL101 for Wet AMD
June 22, 2026
Atsena Doses First Patient in Phase 3 LIGHTHOUSE Trial of Gene Therapy for XLRS
May/June 2026 Insert
Editorially Independent Content, Supported With Advertising From Astellas
Supported by Zeiss
Editorially independent supported by Abbvie and Regenxbio
May/June 2026 Supplement
Free Print Subscription
Email Newsletter
Conference Calendar
